A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
Study sponsor: Novavax
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-11-15Actual
Enrollment · participants660Actual
Source updated2024-05-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.